After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

As of May 22, manufacturers are no longer allowed to distribute the compounded versions of semaglutide, which Novo Nordisk sells under the brand Wegovy for weight loss and Ozempic for diabetes.

Contrave and Wegovy are FDA approved for: weight loss and management, in adults with a body mass index (BMI) of 30 kilograms per square meter (kg/m 2 ) or greater, which indicates obesity ...